AMO-02 for Congenital DM1, Entering Pivotal Trial, Gets Rare Pediatric Disease Status
The U.S. Food and Drug Administration (FDA) has given rare pediatric disease status to AMO Pharma‘s investigational therapy AMO-02 (tideglusib), now entering clinical testing in children and adolescents with congenital myotonic dystrophy type 1 (CDM1), also known as Steinert disease. “This Rare Pediatric Disease designation highlights the significant…